PSS25 - COST-EFFECTIVENESS ANALYSIS OF INTRAVITREAL AFLIBERCEPT VERSUS RANIBIZUMAB IN THE TREATMENT OF DIABETIC MACULAR EDEMA (DME) UNDER THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM (SUS)
Oct 1, 2018, 00:00
10.1016/j.jval.2018.09.2525
https://www.valueinhealthjournal.com/article/S1098-3015(18)35827-3/fulltext
Title :
PSS25 - COST-EFFECTIVENESS ANALYSIS OF INTRAVITREAL AFLIBERCEPT VERSUS RANIBIZUMAB IN THE TREATMENT OF DIABETIC MACULAR EDEMA (DME) UNDER THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM (SUS)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)35827-3&doi=10.1016/j.jval.2018.09.2525
First page :
Section Title :
Open access? :
No
Section Order :
1873